Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs

Psychedelic-assisted therapy: Are psychologists, social workers, and psychiatrists on the same page?

by Eric W. Dolan
October 5, 2023
in Psychedelic Drugs
(Photo credit: Adobe Stock)

(Photo credit: Adobe Stock)

Share on TwitterShare on Facebook

A recent study sheds light on how mental health professionals perceive an emerging form of treatment known as psychedelic-assisted therapy (PAT). The findings reveal intriguing variations in the attitudes and beliefs of psychologists, clinical social workers, and psychiatrists about this innovative approach to mental health care. The research was published in the Journal of Psychedelic Studies.

Psychedelic drugs have long been associated with counterculture movements and recreational use. However, in recent years, they’ve made a comeback in a very different context – mental health treatment. Psychedelic-assisted therapy, which combines psychotherapy with the controlled use of substances like psilocybin (found in magic mushrooms) and MDMA (known as “molly”), has shown promise in treating conditions such as depression, post-traumatic stress disorder (PTSD), and addiction.

“As psychedelic-assisted therapies (PAT) move toward FDA approval, we were interested in understanding how attitudes and beliefs about PAT varied among the professionals expected to be involved in treatment rollout and administration,” explained study author Stacey Bradbury Armstrong, a senior researcher at the Center for Psychedelic Drug Research and Education at The Ohio State University

“More specifically, we wanted to assess how much social workers, psychiatrists, and psychologists were ‘on the same page’ regarding the acceptability of this treatment approach. Having a workforce that is aligned in their attitudes and beliefs around this treatment will be essential, especially as we near the expected and highly anticipated FDA approval of MDMA- and psilocybin-assisted therapies for PTSD and major depressive disorders.”

The study analyzed data from three separate surveys involving these mental health professionals. The participants included psychologists, clinical social workers, and psychiatrists, each providing their unique perspective. The surveys collected information on demographic characteristics such as age, gender, and years of professional experience. They also included questions to gauge participants’ attitudes and beliefs regarding the acceptability and perceived effectiveness of PAT.

Psychologists were recruited via a database of nearly 28,000 email addresses. Two waves of recruitment emails were sent, resulting in 366 psychologists completing the survey. Clinical social workers were recruited through the National Association of Social Workers (NASW). Approximately 7,200 NASW members with a focus on substance use were contacted, and 309 participants completed the survey. Psychiatrists were recruited through various sources, including marketing firms and professional networks. A total of 181 psychiatrists completed the survey.

“Generally speaking, mental health professionals (i.e., social workers, psychiatrists, psychologists) were not aligned in their attitudes and beliefs about PAT,” Armstrong told PsyPost. “Significant differences were observed between at least two professions in terms of understanding PAT, the acceptability of the treatment, how reasonable the approach is, and the belief that PAT would lead to permanent changes.”

Psychiatrists demonstrated a significantly better understanding of PAT compared to social workers. Psychologists expressed significantly higher levels of acceptability for PAT compared to social workers. Psychologists considered PAT significantly more reasonable than both social workers and psychiatrists.

Google News Preferences Add PsyPost to your preferred sources

Social workers were more likely to perceive disadvantages in PAT compared to both psychologists and psychiatrists. Psychologists and psychiatrists were more inclined to believe that PAT could lead to permanent improvements compared to social workers.

“I was struck by how many of our items (5 out of 6) were misaligned,” Armstrong said. “The only item that was consistent among all three mental health professional groups was their confidence that PAT would be effective. And the response for that item was rated as “neutral” across all three professions. Certainly, we have much work to do in preparing our workforce for the expected approval of these treatments, as the first FDA approval could come sometime in 2024.”

While this study provides valuable insights into professional attitudes, it has some limitations. It is based on cross-sectional surveys, which restrict the inferences that can be drawn. Additionally, the recruitment methods varied across the three professional groups, which might have influenced the composition of participants.

“Like all research studies, there are some important considerations with this study. The data for this manuscript came from three separate cross-sectional studies that all asked the same questions about attitudes and beliefs. Therefore, we are limited in the inferences that can be made, specifically around causality,” Armstrong explained.

“Further, because the data came from separate studies, different recruitment methodologies were used, which may have biased who was able to access the study across studies. Lastly, given the topic of the surveys, those who participated in the studies could have been more likely to view PAT favorably.”

Moving forward, these findings underscore the need for education and training programs in psychedelic therapy for mental health professionals. The lack of consensus and knowledge gaps regarding PAT highlight the importance of comprehensive training initiatives to prepare professionals for the evolving landscape of mental healthcare. Addressing concerns related to logistics, time demands, and systemic support is crucial for the successful integration of PAT into existing healthcare systems.

“It is expected that one of the more difficult challenges to overcome as it pertains to this treatment approach, is the availability of trained providers,” Armstrong told PsyPost. “This study supports the expansion of specialized training programs and cross-disciplinary educational initiatives, as these are needed to increase the effectiveness and accessibility of the treatment when it is approved. Focusing on developing our training programs will support the clinical workforce and allow them to get consistent and necessary training across professions.”

The study, “Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States“, was authored by Stacey B. Armstrong, Adam W. Levin, Yitong Xin, Jordan C. Horan, Jason Luoma, Paul Nagib, Brian Pilecki, and Alan K. Davis.

RELATED

Scientists identify key brain mechanism behind ayahuasca’s ability to reduce PTSD symptoms
Ayahuasca

Scientists identify key brain mechanism behind ayahuasca’s ability to reduce PTSD symptoms

February 9, 2026
Lifetime ecstasy use is associated with lower odds of impairments in social functioning, study finds
MDMA

Recreational ecstasy use is linked to lasting memory impairments

February 6, 2026
One specific reason for having sex is associated with higher stress levels the next day
Psilocybin

Psilocybin impacts immunity and behavior differently depending on diet and exercise context

February 4, 2026
Surprising link found between hyperthyroidism and dark personality traits
Depression

Long-term antidepressant effects of psilocybin linked to functional brain changes

January 31, 2026
A dream-like psychedelic might help traumatized veterans reset their brains
Psychedelic Drugs

A dream-like psychedelic might help traumatized veterans reset their brains

January 30, 2026
Major new study finds psilocybin microdoses improve the quality of creative ideas but not the quantity
Microdosing

Major new study finds psilocybin microdoses improve the quality of creative ideas but not the quantity

January 24, 2026
Could MDMA offer new hope for borderline personality disorder treatment?
Depression

MDMA-assisted therapy shows promise for long-term depression relief

January 20, 2026
Does psilocybin really provide long-term relief from depression, as new study suggests?
Microdosing

Psilocybin microdosing fails to boost cognitive performance in rigorous trials

January 19, 2026

STAY CONNECTED

LATEST

Scientists use machine learning to control specific brain circuits

One holiday sees a massive spike in emergency contraception sales, and it isn’t Valentine’s Day

Religiosity may protect against depression and stress by fostering gratitude and social support

Virtual parenting games may boost desire for real children, study finds

Donald Trump is fueling a surprising shift in gun culture, new research suggests

This mental trait predicts individual differences in kissing preferences

Strong ADHD symptoms may boost creative problem-solving through sudden insight

Who lives a good single life? New data highlights the role of autonomy and attachment

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Mental Health
  • Neuroimaging
  • Personality Psychology
  • Social Psychology
  • Artificial Intelligence
  • Cognitive Science
  • Psychopharmacology
  • Contact us
  • Disclaimer
  • Privacy policy
  • Terms and conditions
  • Do not sell my personal information

(c) PsyPost Media Inc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy

(c) PsyPost Media Inc